Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: The POBA study (predictor of bleedings with antiplatelet drugs)

JACC: Cardiovascular Interventions

Volumn 6, Issue 8, 2013, Pages 854-863

  Cuisset, Thomas ^a,b,c   Grosdidier, Charlotte ^b,c,d   Loundou, Anderson Diendonné ^a   Quilici, Jacques ^a,b,c   Loosveld, Marie ^b,c,d   Camoin, Laurence ^c,d   Pankert, Mathieu ^a,c   Beguin, Shirley ^d   Lambert, Marc ^a,b,c   Morange, Pierre Emmanuel ^b,c,d   Bonnet, Jean Louis ^a,b,c   Alessi, Marie Christine ^b,c,d  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

acute coronary syndromes bleeding clopidogrel platelet testing prasugrel

Indexed keywords

CLOPIDOGREL; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIAC PATIENT; CONTROLLED STUDY; CORONARY STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OUTCOME ASSESSMENT; PLATELET REACTIVITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT RESPONSE; VERY LOW ON TREATMENT PLATELET REACTIVITY;

ACS; ACUTE CORONARY SYNDROMES; AREA UNDER THE RECEIVER-OPERATING CURVE; AUC; BARC; BLEEDING ACADEMIC RESEARCH CONSORTIUM; BLEEDING CLOPIDOGREL; BMI; BODY MASS INDEX; CI; CONFIDENCE INTERVAL; HAZARD RATIO; HIGH ON-TREATMENT PLATELET REACTIVITY; HR; HTPR; PCI; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY INDEX VASODILATOR-STIMULATED PHOSPHOPROTEIN; PLATELET TESTING; PRASUGREL; PRI VASP; ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEMI; VERY LOW ON-TREATMENT PLATELET REACTIVITY; VLTPR;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CORONARY THROMBOSIS; DRUG RESISTANCE; FEMALE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHOPROTEINS; PHOSPHORYLATION; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; THIOPHENES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882771753     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.04.009     Document Type: Article

References (31)

1. M.E. Bertrand, H.J. Rupprecht, P. Urban, A.H. Gershlick, and F.T. Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 2000 624 629 (Pubitemid 30640661)
2. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502 (Pubitemid 32758501)
3. S.R. Mehta, S. Yusuf, and R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533 (Pubitemid 32772726)
4. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2005
5. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 36 2009 1045 1057
6. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516 (Pubitemid 46517957)
7. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
8. T. Cuisset, C. Frere, and J. Quilici High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
9. T. Geisler, H. Langer, and M. Wydymus Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425 (Pubitemid 44522148)
10. W. Hochholzer, D. Trenk, and H.P. Bestehorn Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 2006 1742 1750 (Pubitemid 44648629)
11. P. Buonamici, R. Marcucci, and A. Migliorini Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317 (Pubitemid 46891710)
12. T. Cuisset, G. Cayla, and C. Frere Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5 2009 325 329
13. D. Sibbing, S. Schulz, and S. Braun Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
14. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411 (Pubitemid 351447314)
15. T. Cuisset, C. Frere, and J. Quilici Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel non-responders: a prospective, randomized study J Am Coll Cardiol Intv 1 2008 649 653
16. M. Valgimigli, G. Campo, and N. de Cesare Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study Circulation 119 2009 3215 3222
17. M.J. Price, P.B. Berger, and P.S. Teirstein Standard vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
18. D. Trenk, G.W. Stone, and M. Gawaz A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
19. T. Cuisset, M. Loosveld, and P.E. Morange CYP2C19*2 and*17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome J Am Coll Cardiol Intv 5 2012 1280 1287
20. G. Parodi, B. Bellandi, and F. Venditti Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel Am J Cardiol 109 2012 214 218
21. U.R. Schwarz, J. Geiger, U. Walter, and M. Eigenthaler Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects Thromb Haemost 82 1999 1145 1152 (Pubitemid 29419734)
22. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
23. P. Roy, L. Bonello, and R. Torguson Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation Am J Cardiol 102 2008 1614 1617
24. S. Armero, L. Bonello, and J. Berbis Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes Am J Cardiol 108 2011 1710 1713
25. M. Moscucci, K.A. Fox, and C.P. Cannon Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24 2003 1815 1823 (Pubitemid 37280247)
26. S.D. Wiviott, E. Braunwald, D.J. Angiolillo TRITION-TIMI 38 Investigators Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition; With prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
27. G. Montalescot, S.D. Wiviott, and E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST elevation myocardial infarction (TRITON-TIMI 38): double blind, randomised controlled trial Lancet 373 2009 723 731
28. G. Anfossi, and M. Trovati Pathophysiology of platelet resistance to anti-aggregating agents in insulin resistance and type 2 diabetes: implications for anti-aggregating therapy Cardiovasc Hematol Agents Med Chem 4 2006 111 128 (Pubitemid 43805195)
29. J.L. Ferreiro, and D.J. Angiolillo Diabetes and antiplatelet therapy in acute coronary syndrome Circulation 123 2011 798 813
30. S. Zevin, and N.L. Benowitz Drug interactions with tobacco smoking. An update Clin Pharmacokinet 36 1999 425 438 (Pubitemid 29317490)
31. K.P. Bliden, J. Dichiara, and L. Lawal The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 52 2008 531 533